GlassScriptPhysician profile
Bo Song
NPI 1427581446
$6,394.07
in general payments reported to CMS, 2019-2025
25 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 92% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.33 · 2022: $281 · 2023: $2,165 · 2024: $2,247 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,077.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $1,270.87 | 2022-2025 | Xeomin |
| Neurocrine Biosciences, INC. | $1,153.35 | 2023-2025 | Ingrezza |
| Ipsen Biopharmaceuticals, INC | $741.15 | 2021-2025 | Dysport |
| Abbvie INC. | $691.37 | 2022-2025 | Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $411.95 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pacira Pharmaceuticals Incorporated | $370.17 | 2023-2025 | Iovera, Exparel |
| Bioventus LLC | $219.95 | 2023-2025 | Durolane, Xcell, Durolane |
| Pfizer INC. | $198.60 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $195.56 | 2025 | |
| Piramal Critical Care | $160.18 | 2023-2024 | |
| Microtransponder, INC. | $144.17 | 2023 | |
| Medtronic, INC. | $139.37 | 2023-2024 | Synchromedii, Intellis Adaptivestim |
| Acera Surgical, INC. | $125.45 | 2023 | Restrata Wound Matrix |
| Otsuka America Pharmaceutical, INC. | $112.00 | 2023-2025 | Nuedexta |
| Biogen, INC. | $109.42 | 2023-2025 | Spinraza, Spinraza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $89.01 | 2023-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $51.70 | 2022 | |
| Averitas Pharma INC. | $50.25 | 2023 | Qutenza |
| Acadia Pharmaceuticals INC | $34.54 | 2024 | Daybue |
| Amgen INC. | $29.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.85 | 2025 | Relistor |
| Allergan, INC. | $22.23 | 2021 | |
| Scilex Pharmaceuticals INC. | $19.10 | 2023 | Ztlido |
| Ibsa Pharma INC. | $18.61 | 2024 | Licart, Tirosint |
| Idorsia Pharmaceuticals US INC | $12.97 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.